Beacon Pointe Advisors LLC Has $14.02 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Beacon Pointe Advisors LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 19,676 shares of the biopharmaceutical company’s stock after selling 425 shares during the quarter. Beacon Pointe Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $14,015,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Pamalican Asset Management Ltd acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $4,915,000. Intact Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $356,000. Rhenman & Partners Asset Management AB increased its position in Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock worth $30,956,000 after purchasing an additional 4,457 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after acquiring an additional 2,828 shares during the last quarter. Finally, Fagan Associates Inc. raised its stake in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after acquiring an additional 3,832 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price target on the stock. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. The Goldman Sachs Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating for the company in a report on Monday, April 14th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a report on Monday, March 31st. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $945.32.

Regeneron Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ:REGN opened at $610.86 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20. The company has a 50 day moving average of $635.89 and a 200-day moving average of $719.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market cap of $66.78 billion, a price-to-earnings ratio of 15.96, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.